Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Belite Bio Inc ADR

Healthcare US BLTE

143.35USD
-1.11(0.77%)

Last update at 2026-06-05T20:00:00Z

Day Range

138.51146.43
LowHigh

52 Week Range

56.10200.00
LowHigh

Fundamentals

  • Previous Close 144.46
  • Market Cap6603.47M
  • Volume312213
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-84.02400M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.31

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -77.61100M -36.13800M -31.62300M -12.64800M -9.66600M
Minority interest - - - - -
Net income -77.61100M -36.14400M -31.63200M -12.47500M -9.79200M
Selling general administrative 38.83M 10.06M 6.82M 3.95M 2.38M
Selling and marketing expenses - - 0.40M - -
Gross profit - -0.44900M -0.39900M - -
Reconciled depreciation 0.46M 0.45M 0.40M 0.20M 0.03M
Ebit - -36.11800M -31.59800M -12.82100M -9.79700M
Ebitda -84.20800M -35.66900M -31.19900M -12.43400M -9.63600M
Depreciation and amortization - 0.45M 0.40M 0.39M 0.16M
Non operating income net other - - - - -
Operating income -84.20800M -39.99600M -31.66800M -12.82100M -9.79700M
Other operating expenses 84.21M 40.00M 31.67M 12.82M 9.80M
Interest expense 0.00200M 0.02M 0.03M 0.02M 0.00500M
Tax provision 0.00000M 0.00600M 0.00900M 0.00000M 0.00000M
Interest income 6.64M 3.74M 0.07M 0.02M 0.00500M
Net interest income 6.64M 3.72M 0.05M 0.00700M 0.00500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.00600M 0.00900M -0.17300M 0.13M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 84.21M 40.00M 31.67M 12.82M 9.80M
Cost of revenue - 0.45M 0.40M - -
Total other income expense net 6.60M 3.86M 0.04M 0.17M 0.13M
Discontinued operations - - - - -
Net income from continuing ops -77.61100M -36.14400M -31.63200M -12.64800M -9.66600M
Net income applicable to common shares - - - - -9.66600M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 780.56M 152.13M 94.64M 44.27M 18.35M
Intangible assets 4.92M 3.99M 3.23M - -
Earning assets - - - - -
Other current assets 1.13M 1.33M 0.92M 0.72M 0.06M
Total liab 10.07M 6.31M 4.21M 2.77M 33.44M
Total stockholder equity 770.49M 145.82M 90.43M 41.50M -15.09300M
Deferred long term liab - - - - 0.81M
Other current liab 9.64M 5.77M 3.33M 1.91M 1.64M
Common stock 0.00400M 0.00300M 0.00300M 0.00300M 0.00100M
Capital stock 0.00400M 0.00300M 0.00300M 0.00300M 0.00100M
Retained earnings -185.25800M -107.64700M -71.50300M -39.87100M -27.22300M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M - 0.82M
Cash 352.93M 31.68M 88.16M 42.09M 17.34M
Cash and equivalents - - - - -
Total current liabilities 9.88M 6.05M 3.63M 2.10M 1.64M
Current deferred revenue - - - - -
Net debt -352.50300M -31.14000M -87.27100M -41.22300M -17.34400M
Short term debt 0.24M 0.28M 0.31M 0.20M -
Short long term debt - - - - -
Short long term debt total 0.43M 0.54M 0.89M 0.87M -
Other stockholder equity 956.28M 254.12M 162.31M 81.76M 12.32M
Property plant equipment - - - - 0.09M
Total current assets 494.27M 147.07M 89.94M 42.81M 17.43M
Long term investments 280.17M 0.00000M - - -
Net tangible assets - - - - -15.09300M
Short term investments 139.49M 113.47M - - -
Net receivables 0.72M 0.59M 0.87M 0.02M 0.02M
Long term debt - - - - -
Inventory - - - -0.01900M -
Accounts payable - - - - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.53600M -0.66000M -0.37400M -0.39200M -0.19600M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.42M 0.10M 0.17M 0.09M 0.82M
Deferred long term asset charges - - - - -
Non current assets total 286.28M 5.06M 4.70M 1.47M 0.92M
Capital lease obligations 0.43M 0.54M 0.89M 0.87M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -304.92900M -110.57200M -0.06300M -0.39400M -0.05600M
Change to liabilities - - - - 0.04M
Total cashflows from investing activities -305.10700M -110.57200M -0.06300M - -0.05600M
Net borrowings - - - - -
Total cash from financing activities 663.23M 83.59M 75.96M 36.96M -0.58300M
Change to operating activities - - - - 0.59M
Net income -77.61100M -36.14400M -31.63200M -12.64800M -9.66600M
Change in cash 321.25M -56.48000M 46.07M 24.75M -8.27400M
Begin period cash flow 31.68M 88.16M 42.09M 17.34M 25.62M
End period cash flow 352.93M 31.68M 88.16M 42.09M 17.34M
Total cash from operating activities -36.98800M -29.23400M -29.83700M -11.45800M -7.47400M
Issuance of capital stock 182.02M 42.24M 55.19M 0.00000M 0.00000M
Depreciation 0.46M 0.45M 0.40M 0.20M 0.03M
Other cashflows from investing activities - -0.03500M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.06600M 0.07M -0.07200M - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 370.37M 41.36M -1.23000M 36.96M -0.58300M
Change to netincome - - - - 1.52M
Capital expenditures 0.18M 0.15M 0.06M 0.39M 0.07M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.55M 1.13M -2.42700M -0.49100M 0.64M
Stock based compensation 38.92M 8.99M 3.82M 1.48M 1.53M
Other non cash items -1.31300M -3.65900M 4.69M - -0.00800M
Free cash flow -37.16600M -29.38500M -29.90000M -11.85200M -7.54800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BLTE
Belite Bio Inc ADR		 -1.11 0.77% 143.35 - 227.27 - 8.57 -35.6078
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Belite Bio Inc ADR

12750 High Bluff Drive, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of Directors & CEO 1978
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. CFO & Director 1984
Dr. Nathan L. Mata Ph.D. Chief Scientific Officer 1966
Ms. Ching-Chen Chiu M.Sc. VP of Clinical Operations 1970
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of the Board of Directors & CEO 1979
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. CFO & Director 1985
Dr. Nathan L. Mata Ph.D. Chief Scientific Officer 1967
Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board NA
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of the Board of Directors & CEO 1978
Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. Chief Medical Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.